Ocular Therapeutix shifts Axpaxli's approval strategy, raising valuation risks and regulatory uncertainty. Click here to read ...

CatalYm today announced that the first patient has been dosed in the randomized Phase 2b GDFATHER‑NSCLC‑02 (GDF‑15 ...

Capricor Therapeutics faces high regulatory risks for its DMD therapy. Get expert analysis on trial data and FDA challenges.

Relacorilant NDA updates -- FDA PDUFA date set for Dec. 30, 2025 (hypercortisolism); platinum-resistant ovarian cancer PDUFA ...

Ultimately, investigators found a significant reduction in ischemic stroke risk with asundexian compared to placebo, both in combination with antiplatelet therapy. Additionally, participants had no ...

In this episode of Tax Notes Talk, Tax Notes reporters Cady Stanton and Benjamin Valdez discuss the tax credit debate that led to the government shutdown and the potential effects on the IRS and the ...

Onctura initiates phase I/II trial of roginolisib in patients with myelofibrosis who are no longer responding to JAK inhibition: Geneva, Switzerland Friday, December 5, 2025, 15: ...

SINGAPORE,First and only chemotherapy-free combination in the first-line setting to demonstrate an overall survival benefit versus osimertinib among Asian patients.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company advancing ...

When you open Premiere Elements, you first see the Home screen, a separate window from which you can launch any of the three ...

USPTO issues notice of allowance to Mezzion Pharmaceuticals for its udenafil exclusivity in Fontan patients: Fort Lee, New Jersey Saturday, December 6, 2025, 16:00 Hrs [IST] Mezzi ...

A team led by researchers at Penn State have developed a test that can accurately differentiate active HIV infection from ...